All Eylea (afilibercept) articles
-
News
Novo Nordisk manufacturing facility, and clients, hit by FDA action
Regulator classifies former Catalent site as ‘official action indicated’, impacting biotech clients such as Regeneron.
Regulator classifies former Catalent site as ‘official action indicated’, impacting biotech clients such as Regeneron.